On Monday, Shares of Imation Corp. (NYSE:IMN), added 21.63% and closed at $0.769 in the last trading session. The last trading range of the stock ranges between $0.65 and $0.83. Imation Corp. operates as a data storage and data security company worldwide. It provides a range of storage systems and solutions, counting NST hybrid storage line (SAN & NAS), which addresses the hybrid storage market; Nexsan E-Series disk arrays that provide storage density, reliability, and power administration to the block-based storage market; Assureon line, which delivers secure archive systems for data offload, compliance, and secure cloud deployment services; and Transporter line products that deliver private cloud sync and share services for connected workers in security and cost-sensitive work environments. The company serves businesses and individual consumers through distributors, wholesalers, value-added resellers, original equipment manufacturers, and retail outlets.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX), dropped -0.79% and closed at $0.617 in the last trading session. The last trading range of the stock ranges between $0.58 and $0.63. The company’s Market capitalization is $55.40 million with the total Outstanding Shares of 85.12 million. Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, recently declared the distribution of TREXIMET® (sumatriptan and naproxen sodium) 10/60 mg to wholesalers has begun. TREXIMET 10/60 mg is indicated for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.¹ TREXIMET received U.S. Food and Drug Administration (FDA) approval for use in the pediatric population 12 years of age and older in May 2015; however, this formulation just recently became available because of manufacturing delays. The Company anticipates to begin focused product promotion activities in early Q4 2016.
“We are happy to make TREXIMET available for pediatric patients,” said John Sedor, Chairman and CEO of Pernix Therapeutics. “Pediatric migraine sufferers have long represented an underserved patient population,” continued Mr. Sedor. “TREXIMET has the potential to address a noteworthytreatment void for pediatric patients.”
TREXIMET is the only approved combination prescription medicine containing sumatriptan and naproxen sodium for the treatment of acute migraine attacks in pediatric patients. In a study of 490 pediatric patients (ages 12-17), TREXIMET was well tolerated and more effective in providing pain freedom at 2 hours as contrast to placebo.
TherapeuticsMD Inc (NYSEMKT:TXMD), gained 1.17% and closed at $6.89 in the last trading session. The last trading range of the stock ranges between $6.74 and $6.94. During the 52-week trading session the minimum price at which share price traded, registered at $5.18 and reached to max level of $11.26. TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, recently declared the plan of nine posters and oral presentations at forthcoming medical conferences related to Yuvvexy, the conditionally-approved trade name for TX-004HR, an investigational applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), because of menopause.
The presentations support the results from the Yuvvexy clinical development program and further identify women’s perceptions of VVA and current available treatment options. Additional data to be presented provide new insights about the lack of understanding of VVA as a serious medical condition. The posters and presentations will be made at annual meetings of the International Menopause Society (IMS) on September 28 – October 1 in Prague, Czech Republic, and the North American Menopause Society (NAMS) on October 5-8 in Orlando, Florida.